Top Medical News
4 days ago
Persons who had ever injected drugs, either on opiate agonist therapy or not, do not respond to direct-acting antiviral agents (DAA) as well as those who had never used drugs, a new study has shown.
5 days ago
Statins, depending on types and doses, appear to be associated with an increased risk of developing transaminitis or hypertransaminasemia, with the results of a meta-analysis showing that high-dose atorvastatin, rosuvastatin and lovastatin yield higher risks of liver-function test abnormalities.
17 Jun 2019
Cholangitis in adolescence and bilirubin levels ≥21 µmol/L at 16 years of age predict the future need for liver transplant (LT) in young people with biliary atresia, a new study has found.
15 Jun 2019
Cirrhosis is associated with mortality among haemodialysis patients, and those with severe disease have poorer 2-year outcomes, according to a recent study.
08 Jun 2019
Use of aspirin on a daily basis appears to be associated with less severe histologic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, as well as reduce the risk of progression to advanced fibrosis with time, a study has found.
02 Jun 2019
The albumin-bilirubin score, along with platelet count and aspartate aminotransferase-lymphocyte ratio index, is an effective and simple tool for identifying patients at risk of developing hepatocellular carcinoma (HCC) after treatment with direct-acting antivirals (DAA), a new study has found.
30 May 2019
Cyclosporin (CSA) is safe and effective for long-term treatment of autoimmune hepatitis (AIH), a recent study has shown.
Special Reports
04 Dec 2017
Management of locally advanced hepatocellular carcinoma aims to improve survival and to maintain the quality of life of patients, with less likelihood of cure due to the advanced nature of disease. Upon diagnosis of the severity of liver cancer, offering appropriate and proven treatment options is important to extend the survival of these patients.
14 Dec 2016
At the recent Annual Scientific Congress of the Malaysian Society of Gastroenterology and Hepatology (GUT 2016), held at Shangri-La Hotel, Kuala Lumpur, an expert from Hong Kong spoke on the role of direct-acting antivirals as well as pan-genotypic agents that are set to revolutionize hepatitis C treatment.
01 Dec 2016
An expert panel meeting on hepatorenal syndrome (HRS) was recently convened in Kuala Lumpur with the aim of discussing management practices in different hospital settings. Chaired by Professor Sanjiv Mahadeva, consultant gastroenterologist, University Malaya Medical Centre, the meeting saw local and regional experts share HRS cases they have encountered in their practice.
Conference Reports
Roshini Claire Anthony, 10 May 2019

Treatment with the direct-acting antiviral (DAA) combination of glecaprevir and pibrentasvir led to encouraging sustained virological response (SVR) among individuals with hepatitis C virus (HCV) infection, results of two real-world studies presented at the International Liver Congress (ILC 2019) showed.

Roshini Claire Anthony, 07 May 2019

The trend in liver disease-related mortality in individuals with HIV has changed, with a reduction in the incidence of viral hepatitis-related deaths and an increase in non-alcoholic fatty liver disease (NAFLD)-related deaths, according to a study presented at the International Liver Congress (ILC 2019).

Roshini Claire Anthony, 02 May 2019

Patients with non-alcoholic steatohepatitis (NASH) may benefit from treatment with a 25 mg/day dose of obeticholic acid, according to the interim analysis of the phase III REGENERATE* study presented at the International Liver Congress (ILC 2019).

Audrey Abella, 30 Apr 2019
Nonalcoholic fatty liver disease (NAFLD, or steatosis) was prevalent in a substantial number of young adults, suggesting an imminent public health crisis if left undiagnosed and untreated, according to data from a large UK trial presented at ILC 2019.
Roshini Claire Anthony, 29 Apr 2019

Adults with non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH) who progress to advanced liver disease have an elevated risk of mortality compared with non-progressors, according to two separate studies conducted in Germany and France and presented at the International Liver Congress (ILC 2019).

Audrey Abella, 25 Apr 2019
Patients with chronic hepatitis B virus (HBV) infection treated with the nucleot(s)ide analogue tenofovir disoproxil fumarate (TDF) had a lower risk of hepatocellular carcinoma (HCC) than those treated with entecavir, according to data from a large observational study presented at ILC 2019.
Christina Lau, 22 Feb 2018

Cabozantinib, an oral inhibitor of multiple tyrosine kinases, significantly improves overall survival (OS) and progression-free survival (PFS) in patients with advanced hepatocellular carcinoma (HCC) whose disease progressed following sorafenib or other systemic therapies.

CME Modules
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
Sign In To Download